Form 4 for MIRM Mirum Pharmaceuticals, Inc.
Accepted 2023-09-15 00:00:00 ET · period of report 2023-09-13 · accession 0001209191-23-049614 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-09-15 | 2023-09-13 | MIRM | Heron Patrick J | Dir | P - Purchase | $31.02 | +2,625 | 159.1K | +2% | +$81.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-13 | P | A | 2,625 | $31.02 | 159,053 | I By Frazier Life Sciences X, L.P. | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.9633 to $31.0499, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. (F2) The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. |